Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection

Oral Oncology

Volumn 39, Issue 4, 2003, Pages 397-401

  Nicolatou Galitis, Ourania ^a,g   Sotiropoulou Lontou, Anastasia ^b   Velegraki, Aristea ^c   Pissakas, George ^b   Kolitsi, Georgia ^d   Kyprianou, Konstantinos ^d   Kouloulias, Vassilis ^e   Papanikolaou, Ioannis ^f   Yiotakis, Ioannis ^c   Dardoufas, Konstantinos ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b O Aghios Savas Hospital   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d HYGEIA HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

^f UNIVERSITY OF ATHENS   (Greece)

^g NONE   (Greece)

Author keywords

Amifostine; Oral candidiasis; Radiotherapy; Xerostomia

Indexed keywords

AMIFOSTINE; CISPLATIN; FLUCONAZOLE; FLUOROURACIL; RADIOPROTECTIVE AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; PRIORITY JOURNAL; RADIATION PROTECTION; RATING SCALE; SALIVARY GLAND; THRUSH; XEROSTOMIA;

AMIFOSTINE; CANDIDIASIS, ORAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; MIDDLE AGED; MOUTH NEOPLASMS; NASOPHARYNGEAL NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; SALIVARY GLANDS;

EID: 0037409241     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(02)00144-6     Document Type: Article

References (28)

1. Pratt N.E., Sodicoff M., Liss J., Davis M., Sinesi M. Radioprotection of the rat parotid gland by WR-2721: morphology at 60 days post-irradiation. Int J Radiation Oncology Biol Phys. 6:1980;431-435.
2. Nicolatou O. Morphologic changes in rat parotid following isoproterenol administration and fractionated X-irradiation. J Oral Pathol. 10:1981;311-321.
3. Shannon I.L., Starcke E.N., Wescott W.B. Effect of radiotherapy on whole saliva flow. J Dent Res. 56:1977;693.
4. Wescott W.B., Mira J.G., Starcke E.N., Shannon I.L., Thornby J.I. Alterations in whole saliva flow rate induced by fractionated radiotherapy. Am J Roentgenol. 130:1978;145-149.
5. Cheng V.S.T., Downs J., Herbert D., Aramany M. The function of the parotid gland following radiation therapy for head and neck cancer. Int J Radiation Oncology Biol Phys. 7:1981;253-258.
6. Makkonen T.A., Nordman E. Estimation of long-term salivary gland damage induced by radiotherapy. Acta Oncologica. 26:1987;307-312.
7. Markitziu A., Zafiropoulos G., Tsalikis L., Cohen L. Gingival health and salivary function in head and neck-irradiated patients. Oral Surg Oral Med Oral Pathol. 73:1992;427-433.
8. Valdez I.H., Atkinson J.C., Ship J.A., Fox P. Major salivary gland function in patients with radiation-induced xerostomia: flow rates and sialometry. Int J Radiat Oncol Biol Phys. 25:1992;41-47.
9. Silverman S. Jr., Luangjarmekorn L., Greenspan D. Occurrence of oral candida in irradiated head and neck cancer patients. J Oral Med. 39:1984;194-196.
10. Rossie K.M., Taylor J., Beck F.M., Hodgson S.E., Blozis G.G. Influence of radiation therapy on oral Candida albicans colonization: a quantitative assessment. Oral Surg Oral Med Oral Pathol. 64:1987;698-701.
11. Epstein J.B., Freilich M.M., Nhu D. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol. 76:1993;169-174.
12. Ramirez-Amador V., Silverman S. Jr., Mayer P., Tyler M., Quivey J. Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 84:1997;149-153.
13. Mucke R., Kaben U., Libera T. Fluconazole prophylaxis in patients with head and neck tumors undergoing radiation and radiochemotherapy. Mycoses. 41:1998;421-423.
14. Redding S.W., Zellars R.C., Kirkpatrick W.R.et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol. 37:1999;3896-3900.
15. Makkonen T.A., Minn H., Jekunen A., Vilja P., Tuominen J., Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. Int J Radiation Oncology Biol Phys. 46:2000;525-534.
16. Nicolatou-Galitis O., Dardoufas K., Markoulatos P.et al. Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. J Oral Pathol Med. 30:2001;471-480.
17. Schwarz E., Chiu G.K.C., Leung W.K. Oral health status of southern Chinese following head and neck irradiation therapy for nasopharyngeal carcinoma. J Dent. 27:1999;21-28.
18. Spak C.J., Johnson G., Ekstrand J. Caries incidence, salivary flow rate and efficacy of fluoride gel treatment in irradiated patients. Caries Res. 28:1994;388-393.
19. Morrish R.B., Chan E., Silverman S. Jr., Meyer J., Fu K.K., Greenspan D. Osteonecrosis in patients irradiated for head and neck carcinoma. Cancer. 47:1981;1980-1983.
20. McDonald S., Meyerowitz C., Smudzin T., Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiation Oncology Biol Phys. 29:1994;747-754.
21. Buntzel J., Kuttner K., Frohlich D., Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 9:1998;505-509.
22. Wagner W., Prott F.J., Schonekas K.G. Amifostine: a radioprotector in locally advanced head and neck tumors. Oncology Reports. 5:1998;1255-1257.
23. Brizel D.M., Wasserman T.H., Henke M.et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 18:2000;3339-3345.
24. Wasserman T., Mackowiak J.I., Brizel D.M.et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiation Oncology Biol Phys. 48:2000;1035-1039.
25. Rudat V., Meyer J., Momm F.et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiation Oncology Biol Phys. 48:2000;1339-1343.
26. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA 1997.
27. Velegraki A., Papalambrou D., Soremi S., Legakis N.J. Variable antifungal susceptibility of wild-type Candida albicans phenotypes from neutropenic hosts. Eur J Clin Microbiol Infect Dis. 15:1996;854-860.
28. Nicolatou O., Sotiropoulou-Lontou A., Skarlatos J., Kyprianou K., Kolitsi G., Dardoufas K. A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report. Int J Radiation Oncology Biol Phys. 42:1998;551-556.